Skip to main content


Press Releases


Press Release

BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program

July 17, 2023
Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS Underpinned by proprietary…
Press Release

BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program

April 24, 2023
Encouraging non-human primate (NHP) findings support the progression of IV-formulated BMD-001 ahead of formal clinical studies for…
Press Release

BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer

April 5, 2023
CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 — BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and…
Press Release

BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies

March 27, 2023
CAMBRIDGE, Mass. and DAEJEON, South Korea, March 27, 2023 — BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and…
Press Release

BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events

March 14, 2023
CAMBRIDGE, Mass. and DAEJEON, South Korea, March 8, 2023 /PRNewswire/ — BIORCHESTRA, a biotherapeutics company focused on the treatment of rare…
Press Release

BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy

December 15, 2022
A leader in creating jobs through the advancement of RNA-based therapeutics A contributor to a…
Press Release

BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology

August 23, 2022
BIORCHESTRA, headquartered in Daejeon, South Korea, appointed Dr. Gabriel Helmlinger (Ph.D., D.A.B.T.) as Vice-President, Head of Translational &…
Press Release

BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer’s disease and drug delivery system technology at the 2022 BIO International Convention

June 9, 2022
BIORCHESTRA Co., Ltd (BIORCHESTRA), is scheduled to give a company presentation on June 16, 12:00 at…
Press Release

BIORCHESTRA Participated in Formulation and Delivery

May 12, 2022
BIORCHESTRA is a leading RNA therapeutics company that develops novel RNA-based therapeutics and drug delivery…
Press Release

BIORCHESTRA Announces 45 Million USD Series C Fundraising

February 22, 2022
BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using…
Press Release

BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics

January 5, 2022
BIORCHESTRA and SK Biopharmaceuticals announced today that they have forged a partnership to research and…
Press Release

BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO “Dr. Louis St. L. O’Dea” as CMO of BIORCHESTRA

September 23, 2021
BIORCHESTRA is a bio-tech company focused on the identification of novel targets in neurodegenerative diseases…
Press Release

Biorchestra Named Awardee in NYC Innovation QuickFire Challenge on Neuroscience

June 24, 2021
Johnson & Johnson Innovation announced today that Biorchestra has been selected as the awardee in…
Press Release

Biorchestra “Discussing the Material Transfer Agreement (MTA) with Big Pharma for Alzheimer’s treatment”

June 25, 2020
Biorchestra announced on the 25th that it has received a proposal for a material transfer…
Press Release

Chong Kun Dang invests ₩5 billion in Biorchestra

August 21, 2019
Chong Kun Dang Holdings said that would invest 5 billion won ($4.1 million) in Biorchestra…